Evidence map›Paper›PMID 37500709›Full record

ArticleScientific reports2023

Association between enhanced carbonyl stress and decreased apparent axonal density in schizophrenia by multimodal white matter imaging.

Shuraku Son, Makoto Arai, Kazuya Toriumi, Christina Andica, Daisuke Matsuyoshi, Koji Kamagata, Shigeki Aoki, Takahiko Kawashima, Takanori Kochiyama, Tomohisa Okada and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Shuraku SonDepartment of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Makoto AraiProject for Schizophrenia Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kazuya ToriumiProject for Schizophrenia Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Christina AndicaDepartment of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Daisuke MatsuyoshiInstitute of Quantum Life Science, National Institutes for Quantum Science and Technology, Takasaki, Japan.
Koji KamagataDepartment of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shigeki AokiDepartment of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takahiko KawashimaDepartment of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Takanori KochiyamaBrain Activity Imaging Center, ATR-Promotions, Kyoto, Japan.
Tomohisa OkadaHuman Brain Research Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasutaka FushimiDepartment of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuji NakamotoDepartment of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuko KobayashiDepartment of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Toshiya MuraiDepartment of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Masanari ItokawaProject for Schizophrenia Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Jun MiyataDepartment of Psychiatry, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-Ku, Kyoto, 606-8507, Japan. miyata10@kuhp.kyoto-u.ac.jp.
Kyoto University · JPJuntendo University · JPTokyo Metropolitan Institute of Medical Science · JPHoya (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbonyl stress is a condition featuring increased rich reactive carbonyl compounds, which facilitate the formation of advanced glycation end products including pentosidine. We previously reported the relationship between enhanced carbonyl stress and disrupted white matter integrity in schizophrenia, although which microstructural component is disrupted remained unclear. In this study, 32 patients with schizophrenia (SCZ) and 45 age- and gender-matched healthy volunteers (HC) were recruited. We obtained blood samples for carbonyl stress markers (plasma pentosidine and serum pyridoxal) and multi-modal magnetic resonance imaging measures of white matter microstructures including apparent axonal density (intra-cellular volume fraction (ICVF)) and orientation (orientation dispersion index (ODI)), and inflammation (free water (FW)). In SCZ, the plasma pentosidine level was significantly increased. Group comparison revealed that mean white matter values were decreased for ICVF, and increased for FW. We found a significant negative correlation between the plasma pentosidine level and mean ICVF values in SCZ, and a significant negative correlation between the serum pyridoxal level and mean ODI value in HC, regardless of age. Our results suggest an association between enhanced carbonyl stress and axonal abnormality in SCZ.

Indexed as

SchizophreniaWhite MatterAxonsGlycation End Products, AdvancedHumansPyridoxalGlycation End Products, AdvancedPyridoxal

Identifiers

PMID37500709
PMCPMC10374594
OpenAlexW4385323551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.